192P - Colorectal cancer care in Yangon General Hospital

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Colon and Rectal Cancer
Rectal Cancer
Presenter Hlaing Maw
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors H.H. Maw
  • Medical Oncology, Yangon General Hospital, 11142 - Yangon/MM



CRC is the third most common cancer in men and the fourth in woman, in Myanmar. In the past years incidence of CRC steadily increased. So we explored the CRC case-load and line of management to assess the status of CRC care.


This descriptive study was undertaken in Medical Oncology Department in YGH, the main tertiary hospital in our country. All histologically proved CRC cases registered from October 2014 to September 2015 were involved. Data regarding patient's particulars, clinical presentations, histology, staging, treatment given and outcomes during a median follow-up period 6months (range 4- 14) were recorded. Data analysis was done to describe the results.


A total of 293 patients were involved, 151 female (51.53%) and 142 male (48.46%). Median age was 52 years (range 19-89).Rectum is the most common site (62.82%). Majority of patients presented with passing blood and mucous stool. The most common histology was adenocarcinoma (62.52%). Adenoma-carcinoma sequence was detected in 29(9.89%). Majority were in stage 2B (38.51%) and metastatic diseases were found in 22.26%.Common metastatic sites were peritoneum and omentum. Among surgically treated patients, 67.23% received radical surgery. Only 58.35% of registered patients took chemotherapy and among them 105 patients (61.4%) received continuous infusion of FU/LV. Grade 3 to 4 neutropenia was observed in 14.47%. Among patients with non-metastatic rectal cancer, only 41.49% were agreed to take EBRT (50 cGy). None of them received neoadjuvant RT. 102 were lost to take further management after surgery and another 35 patients were lost to attend follow-up clinic. Among the rest of the patients, 65.78% were progression free and 34.21% had disease progression or tumour recurrence during follow-up period.


Fortunately, majority of patients received radical surgery, the mainstay treatment of CRC. But significant numbers of patients were lost to take further needful management. Advantage of chemotherapy with manageable toxicity can be observed. Strategies to improve patients' health education and to develop screening program and better advanced treatment are needed to upgrade our CRC care.

Clinical trial indentification

This was a descriptive study conducted for clinical experience.

Legal entity responsible for the study

Medical Oncology Department, Yangon General Hospital.


Medical Oncology Department, YGH.


All authors have declared no conflicts of interest.